Scandinavian Medical Solutions (One-pager): The foundation is now built for the next growth phase
Yesterday, Scandinavian Medical Solutions reported its 2023/24 results and announced its new 2024/25 guidance. The 2023/24 results were within the company's guidance, and the new guidance ranges for 2024/25 correspond to between 6-19% revenue growth and an EBITDA margin between 9-12%.
After investments in 2023/24, including in the organization and infrastructure, the US subsidiary, and its Aftersales & Parts and Rental business areas, the foundation is now built for the next growth phase.
We have updated our investment case one-pager following the 2023/24 results, new 2024/25 guidance, and recent news. Besides an overview of financials and valuation multiples, the investment case one-pager introduces Scandinavian Medical Solutions and highlights key investment reasons and risks.
Earlier today, Scandinavian Medical Solutions' CEO Jens Hvid Paulsen and Head of Sales Martin Lind presented the 2023/24 report and new expectations in an online live event (in Danish). Watch the presentation here: https://www.inderes.dk/videos/scandinavian-medical-solutions-praesentation-af-arsrapporten-202324
Disclaimer: HC Andersen Capital receives payment from Scandinavian Medical Solutions for a Digital IR/Corporate Visibility subscription agreement. /Kasper Lihn 15:00, 21 November 2024.
Login required
This content is only available for logged in users
Scandinavian Medical Solutions
Scandinavian Medical Solutions är verksamt inom vård och omsorg. Bolaget är en dansk återförsäljare av bilddiagnostikutrustning. Produktutbudet inkluderar CT- och MR-skannrar samt ultraljudsenheter och röntgenutrustning. Bolaget bedriver sin försäljning globalt och kunderna återfinns främst bland sjukhus. Scandinavian Medical Solutions grundades 2019 och har sitt huvudkontor i Aalborg.
Read more on company page